SP免疫组化染色检测IGF-1及组织P53蛋白的表达在结直肠腺癌中意义

来源期刊：广州医药 | 1269-1274 发布时间：2024-12-02 收稿时间：2025/11/13 18:42:59 阅读量：17

作者：: 田彩云,

田莉,

王春玲,

杜亚娟,

杨利,

关键词：: 免疫组化染色胰岛素样生长因子-1 P53 结直肠腺癌; immunohistochemical staining insulin like growth factor-1 P53 colorectal cancer

DOI：: 10.20223/j.cnki.1000-8535.2024.11.005

收稿时间：: 2024-02-18
修订日期：
接收日期：
引用总数：: 0

目的探讨链霉菌抗生物素蛋白-过氧化物酶（SP）免疫组化染色检测胰岛素样生长因子-1（IGF-1）及组织P53蛋白的表达在结直肠腺癌中意义。方法选取乌鲁木齐市中医医院2020年1月—2023年12月收治的169例结直肠腺癌患者为恶性组,另选取我院同期收治的169例良性结直肠肿瘤患者为良性组。取手术或活检病理组织应用SP免疫组化染色检测2组肿瘤组织IGF-1及P53蛋白表达水平,对比良性组与恶性组间差异,分析不同临床分期、淋巴结转移情况及组织分化程度患者的IGF-1水平、IGF-1mRNA及P53蛋白阳性率。结果 SP免疫组化染色检测IGF-1阳性率、P53蛋白阳性率,恶性组（72.78%、47.93%）均高于良性组（14.79%、6.51%）,对比差异有统计学意义（χ²=115.440、χ²=73.180,P<0.05）;Ⅳ期患者IGF-1阳性率（96.77%）及P53蛋白阳性率（77.42%）高于Ⅲ期（85.11%、63.83%）、Ⅱ期（62.69%、31.34%）及Ⅰ期患者（45.83%、25.00%）,对比差异有统计学意义（χ²=24.860,χ²=28.000,P<0.05）,各亚组两两比较差异无统计学意义（IGF-1阳性与阴性,Ⅰ期 vs Ⅲ期,χ²=12.110,P<0.001;Ⅰ期 vs Ⅳ期,χ²=16.060,P<0.001;Ⅱ期 vs Ⅲ期,χ²=6.880,P=0.009;P53蛋白阳性与阴性Ⅰ期 vs Ⅲ期,χ²=9.580,P<0.002;Ⅰ期 vs Ⅳ期,χ²=14.9990,P<0.001;Ⅱ期 vs Ⅲ期,χ²=11.790,P=0.001;）;有淋巴结转移患者IGF-1阳性率（85.71%）及P53蛋白阳性率（71.43%）高于无淋巴结转移患者（14.79%、40.94%）,对比差异有统计学意义（χ²=4.720、11.740,P<0.05）;低分化患者IGF-1阳性率（93.48%）及P53蛋白阳性率（71.74%）高于中分化患者（81.18%、54.12%）、高分化患者（52.63%、31.58%）,对比差异有统计学意义（χ²=21.250、13.510,P<0.05）。结论 SP免疫组化染色检测提示结直肠腺癌患者IGF-1、P53蛋白阳性率高于良性肿瘤患者,且临床分期高、淋巴结转移与肿瘤组织低分化者的IGF-1、P53蛋白阳性率高,因此IGF-1、P53有望成为结直肠腺癌诊治的重要检测指标。

Objective Exploring the significance of immunohistochemical staining with streptavidin-perosidase（SP）to detect the expression of insulin-like growth factor-1（IGF-1）and tissue P53 in colorectal adenocarcinoma．Methods A total of 169 patients with colorectal adenocarcinoma admitted to a hospital from January 2020 to December 2023 were selected and divided into the malignant group．Other 169 patients with benign colorectal tumors admitted to a hospital during the same period were selected and divided into the benign group．SP immunohistochemistry staining was used to detect and compare the expression levels of IGF-1 and P53 proteins in two groups of tumor tissues obtained in surgery or biopsy．And the IGF-1 levels,IGF-1 mRNA,and P53 positivity rates in patients with different clinical stages,lymph node metastasis,and tissue differentiation levels were compared．Results There was a significant difference in the positive rates of IGF-1mRNA and P53 detected by SP immunohistochemistry staining,and malignant group（72.78%,47.93%）were higher than the benign group（14.79%,6.51%）,which were statistically significant（χ²=115.440,73.180,P<0.05）．The positive rates of IGF-1 and P53 were 96.77% and 77.42% in stage IV,which were higher than those in Stage III（85.11%,63.83%）,II（62.69%,31.34%）and I（45.83%,25.00%）,the differences were statistically significant（χ²=24.860,28.000,P<0.05）．The expression levels of IGF-1 and P53 in colorectal adenocarcinoma patients with different lymph node metastases showed significant differences,the positive rates of IGF-1（85.71%）and P53（71.43%）in patients with lymph node metastasis were higher than those without lymph node metastasis（14.79%,40.94%）,and the differences were statistically significant（χ²=4.720,11.740,P<0.05）．There were significant differences in the expression levels of IGF-1 and P53 among patients with colorectal adenocarcinoma of different degrees of differentiation,the positive rates of IGF-1（93.48%）and P53（71.74%）were significantly higher than those of moderately differentiated（81.18%,54.12%）and well differentiated（52.63%,31.58%）,and the differences were statistically significant（χ²=21.250,13.510,P<0.05）．Conclusion sThrough SP immunohistochemical staining,it was found that the positivity rates of IGF-1 and P53 in colorectal adenocarcinoma patients were higher than those in benign tumor patients,and those with high the clinical stage,lymph node metastasis,and low differentiation of tumor tissue,had higher the positivity rates of IGF-1 and P53．Therefore,IGF-1 and P53 are expected to become important monitoring indicators for the diagnosis and treatment of colorectal adenocarcinoma．

1、沈凯,刘彤.肝细胞癌组织p53凋亡刺激蛋白2表达及临床意义[J].浙江医学,2023,45(2):121-124,149.

2、张萌,景梦园,曹云太,等.表观扩散系数在术前预测子宫内膜癌肌层浸润、Ki-67和P53表达水平的临床价值[J].磁共振成像,2023,14(7):78-85.

3、 LIU H,GU H,KUTBI EH,et al.Association of IGF-1 and IGFBP-3 levels with gastric cancer:A systematic review and meta-analysis[J].Int J Clin Pract,2021,75(11):e14764.

4、廖渝,荣长仙,黄雪梅,等.血清铁蛋白、胰岛素样生长因子-1、纤维蛋白原在卵巢癌中的表达及与病情严重程度的相关性[J].临床和实验医学杂志,2022,21(17):1863-1866.

5、刘秀虹,马玉坤,涂博,等.胰岛素样生长因子-1和Ki-67在中耳胆脂瘤中的表达[J].中华耳科学杂志,2023,21(3):372-377.

6、牛姝,孙政,高海娜,等.胰岛素样生长因子1受体在结直肠腺癌合并2型糖尿病患者中的表达情况及其与临床特征的关系研究[J].实用心脑肺血管病杂志,2023,31(4):78-82.

7、高超,郑晨,黄新,等.同源盒A10和P53蛋白在结直肠腺癌中的表达及其临床意义[J].中华普通外科学文献(电子版),2023,17(1):40-44.

8、陈功泉,石琳,胡卯秀,等.三阴性乳腺癌的超声图像特征及其与P53、BRCA1蛋白表达的相关性[J].临床超声医学杂志,2021,23(6):406-409.

9、王彦龙,肖兰,朱丽娜,等.不同p53表达乳腺癌临床病理特征及MRI表现对照分析[J].四川医学,2021,42(2):162-166.

10、张馨月,陈亮,郑宇.血清C肽和胰岛素样生长因子结合蛋白3与乳腺癌患者死亡风险相关性分析[J].检验医学,2022,37(1):36-40.

11、杨昆鑫,方学森,金政,等.胰岛素样生长因子1抑制高糖诱导大鼠胃平滑肌细胞内质网应激及其机制的研究[J].中国糖尿病杂志,2020,28(4):286-291.

12、章小霞,王燕,袁明明,等.子宫内膜癌组织中HAX1和突变型p53表达的相关性及其临床意义[J].现代肿瘤医学,2023,31(3):497-503.

13、 REZAEI S,de OLIVEIRA LC,GHANAVATI M,et al.The effect of anamorelin(ONO-7643)on cachexia in cancer patients:Systematic review and meta-analysis of randomized controlled trials[J].J Oncol Pharm Pract,2023,29(7):1725-1735.

14、魏东,辛运超,刘博,等.pN0期非小细胞肺癌VEGF、Ki-67、p53表达与淋巴结微转移的相关性[J].蚌埠医学院学报,2023,48(5):586-589.

15、王现生,于红艳,郭小燕.非小细胞肺癌组织中TRIM59、p53表达与临床病理特征及预后的相关性分析[J].局解手术学杂志,2023,32(1):9-14.

16、林伟强,袁惠玲,温润耀,等.浸润性乳腺癌患者组织P120ctn p53及CK5/6表达及意义分析[J].河北医学,2023,29(2):259-265.

17、吴鹏杰,张伟,刘圣杰,等.P53、Ki-67蛋白在前列腺癌的表达及其临床意义[J].现代泌尿外科杂志,2023,28(5):421-423.

18、中国医师协会结直肠肿瘤专业委员会外科专委会.中国结直肠癌县域医师诊疗指南-外科部分(2019版草案)[J].中华结直肠疾病电子杂志,2019,8(5):433-438.

19、许儒,阴鲁鑫,华磊,等.ATRX、P53表达的相关性及联合多因素对胶质瘤预后的意义[J].临床神经外科杂志,2023,20(2):153-157,162.

20、吴志涛,上官伦,徐冰洁.周围型肺癌CT征象与Ki-67、p53表达的关系[J].分子影像学杂志,2023,46(1):124-128.

21、魏伟,赵慧娟,刘湘翠.USP7-MDM2-p53信号轴对子宫内膜癌细胞增殖、凋亡和细胞周期的影响[J].现代肿瘤医学,2024,32(2):214-220.

22、 JI X,FU J,LI X,et al.Serum biomarkers of colonic polyps in patients with acromegaly:A meta-analysis and systematic review[J].Pituitary,2023,26(1):1-8.

23、 LARSSON SC,BURGESS S.Causal role of high body mass index in multiple chronic diseases:A systematic review and meta-analysis of Mendelian randomization studies[J].BMC Med,2021,19(1):320.

24、 IRRAZABAL T,THAKUR BK,CROITORU K,et al.Preventing colitis-associated colon cancer with antioxidants:A systematic review[J].Cell Mol Gastroenterol Hepatol,2021,11(4):1177-1197.

25、 CUK P,KJ?R MD,MOGENSEN CB,et al.Short-term outcomes in robot-assisted compared to laparoscopic colon cancer resections:A systematic review and meta-analysis[J].Surg Endosc,2022,36(1):32-46.